These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 31983199

  • 21. Stability and Biosimilarity Assessment of Bevacizumab Monoclonal Antibody; Orthogonal Testing Protocol Coupled With Peptide Mapping-Principal Component Analysis.
    Abdelghaffar SH, Hegazy MA, Eltanany BM.
    J AOAC Int; 2024 Jan 04; 107(1):177-188. PubMed ID: 37606972
    [Abstract] [Full Text] [Related]

  • 22. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
    Chen L, Wang L, Shion H, Yu C, Yu YQ, Zhu L, Li M, Chen W, Gao K.
    MAbs; 2016 Oct 04; 8(7):1210-1223. PubMed ID: 27380163
    [Abstract] [Full Text] [Related]

  • 23. A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability.
    Chirio D, Peira E, Sapino S, Chindamo G, Oliaro-Bosso S, Adinolfi S, Dianzani C, Baratta F, Gallarate M.
    Pharmaceutics; 2021 Apr 15; 13(4):. PubMed ID: 33921167
    [Abstract] [Full Text] [Related]

  • 24. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L.
    Biologicals; 2022 Jun 15; 77():1-15. PubMed ID: 35667958
    [Abstract] [Full Text] [Related]

  • 25. Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product.
    Seo N, Guan X, Wang T, Chung HSH, Wikström M, Padaki R, Kalenian K, Kuhns S, Matthies K, Crouse-Zeineddini J, Wong HY, Ng M, Foltz IN, Cao S, Liu J.
    Ophthalmol Ther; 2024 May 15; 13(5):1303-1320. PubMed ID: 38507189
    [Abstract] [Full Text] [Related]

  • 26. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions.
    Weiser S, Burns C, Zartler ER.
    J Oncol Pharm Pract; 2023 Jul 15; 29(5):1032-1043. PubMed ID: 35312402
    [Abstract] [Full Text] [Related]

  • 27. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH, Lee J, Bae JS, Kim YJ, Kang HA, Kim SH, Lee SJ, Lim KJ, Lee JW, Jung SK, Chang SJ.
    MAbs; 2018 Apr 15; 10(3):380-396. PubMed ID: 29469653
    [Abstract] [Full Text] [Related]

  • 28. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
    Singh SK, Kumar D, Malani H, Rathore AS.
    Sci Rep; 2021 Jan 29; 11(1):2487. PubMed ID: 33514790
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
    Jiang X, Zhang QL, Liu TG, Zhao WP, Yang M, Wang LN, Sun WL, Pan L, Luo AP, Huang JC, Gu XH.
    Curr Pharm Des; 2019 Jan 29; 25(8):862-870. PubMed ID: 30848190
    [Abstract] [Full Text] [Related]

  • 30. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J, Lee Y, Lee C, Eo S, Kim S, Lee N, Park J, Park S, Seo D, Jeong M, Lee Y, Yeon S, Bou-Assaf G, Sosic Z, Zhang W, Jaquez O.
    MAbs; 2017 Jan 29; 9(2):364-382. PubMed ID: 28005456
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, Zhang W, Lyubarskaya Y.
    MAbs; 2016 Jan 29; 8(6):1136-55. PubMed ID: 27246928
    [Abstract] [Full Text] [Related]

  • 32. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
    Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S, Pagès G.
    Eur J Cancer; 2010 Nov 29; 46(16):3022-36. PubMed ID: 20729074
    [Abstract] [Full Text] [Related]

  • 33. Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab.
    Quiñonez-Alvarado MG, Chávez-Hurtado P, Caro-Palomera JC, Niño-Trejo OL, Jiménez-Dolores JI, Muñoz-Villegas P, Baiza-Durán L, Quintana-Hau JD.
    Biologicals; 2023 Nov 29; 84():101711. PubMed ID: 37748325
    [Abstract] [Full Text] [Related]

  • 34. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
    Bhattacharya S, Rathore AS.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep 01; 1229():123896. PubMed ID: 37776677
    [Abstract] [Full Text] [Related]

  • 35. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function.
    Kang J, Kim SY, Vallejo D, Hageman TS, White DR, Benet A, Coghlan J, Sen KI, Ford M, Saveliev S, Tolbert TJ, Weis DD, Schwendeman SP, Ruotolo BT, Schwendeman A.
    Eur J Pharm Biopharm; 2020 Jan 01; 146():111-124. PubMed ID: 31841688
    [Abstract] [Full Text] [Related]

  • 36. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
    Magnenat L, Palmese A, Fremaux C, D'Amici F, Terlizzese M, Rossi M, Chevalet L.
    MAbs; 2017 Jan 01; 9(1):127-139. PubMed ID: 27854156
    [Abstract] [Full Text] [Related]

  • 37. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S, Yamamoto K, Muniz R, Iwura T.
    Pharmacol Res Perspect; 2020 Jun 01; 8(3):e00604. PubMed ID: 32500668
    [Abstract] [Full Text] [Related]

  • 38. Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
    Jiang Y, Arora T, Klakamp S, Davis J, Chandrasekher YA, Young G, Du Y, Yu B, Miller KJ.
    Drugs R D; 2023 Dec 01; 23(4):377-395. PubMed ID: 37632627
    [Abstract] [Full Text] [Related]

  • 39. Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies.
    Wang L, Xu GL, Gao K, Wilkinson J, Zhang F, Yu L, Liu CY, Yu CF, Wang WB, Li M, Chen W, Fan F, Cong M, Wang JZ.
    J Pharm Biomed Anal; 2016 Jun 05; 125():212-8. PubMed ID: 27042807
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D, Kim J, Yun J, Park SJ.
    Adv Ther; 2020 Oct 05; 37(10):4308-4324. PubMed ID: 32816233
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.